ArticleMedical oncology (Northwood, London, England)2013
High expression of PRDM14 correlates with cell differentiation and is a novel prognostic marker in resected non-small cell lung cancer.
Article in Medical oncology (Northwood, London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- Growth factor receptors IGF-1R and VEGFR2 are associated with the prognosis of patients with esophageal cancer after esophagectomy.Open life sciences · 2026Article
- Functional and molecular single-cell analyses implicate PRDM14 in the initiation of B cell leukemia in mice.Scientific reports · 2025Article
- Therapeutic siRNA targeting the cancer cell stemness regulator PRDI-BF1 and RIZ domain zinc finger protein 14.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2022Article
- Mucosal ribosomal stress-induced PRDM1 promotes chemoresistance via stemness regulation.Communications biology · 2021Article
- Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk.BMC cancer · 2020Article
- PRDM14 promotes malignant phenotype and correlates with poor prognosis in colorectal cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020Article
- Multifaceted Role of PRDM Proteins in Human Cancer.International journal of molecular sciences · 2020Review
- The Pluripotency Regulator PRDM14 Requires Hematopoietic Regulator CBFA2T3 to Initiate Leukemia in Mice.Molecular cancer research : MCR · 2019Article
- Off to a Bad Start: Cancer Initiation by Pluripotency Regulator PRDM14.Trends in genetics : TIG · 2019Review
- Integrated Analysis of Genetic Abnormalities of the Histone Lysine Methyltransferases in Prostate Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- Targeted DamID reveals differential binding of mammalian pluripotency factors.Development (Cambridge, England) · 2018Article
- PRDM14 is expressed in germ cell tumors with constitutive overexpression altering human germline differentiation and proliferation.Stem cell research · 2018Article
- PRDM14 directly interacts with heat shock proteins HSP90α and glucose-regulated protein 78.Cancer science · 2018Article
- The methylation profiles of PRDM promoters in non-small cell lung cancer.OncoTargets and therapy · 2018Article
- Silencing PRDM14 expression by an innovative RNAi therapy inhibits stemness, tumorigenicity, and metastasis of breast cancer.Oncotarget · 2017Article
- PRDM5 promotes the proliferation and invasion of murine melanoma cells through up-regulating JNK expression.Cancer medicine · 2016Article
- PRDM14 promotes RAG-dependent Notch1 driver mutations in mouse T-ALL.Biology open · 2016Article
- [Research Progress of PR Domain Zinc Finger Protein 14].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2016Review
- Article
- Amplification of chromosome 8 genes in lung cancer.Journal of Cancer · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PR (PRDI-BF1 and RIZ) domain containing proteins (PRDM) have been indicated to play important roles in several human cancers. The objectives of this study were to determine the frequency and prognostic significance of PRDM1 and PRDM14 expression in a cohort of surgically resected non-small cell lung cancer (NSCLC) patients. Immunohistochemistry and Western blotting was used to detect the expression status of PRDM1 in primary tumors and PRDM14 for both primary lung cancers and matched lymph node metastases. Univariate and multivariate analysis were performed to determine the association between PRDM expression and prognosis. PRDM1 expression was observed in all NSCLC patients' tumor samples. PRDM14 was found to be increased expression in 35.65 % cases (46/129) for primary tumors and 39.68 % cases (25/63) for paired metastatic lymph nodes. Increased expression of PRDM14 correlated with differentiation of tumor cells significantly (P = 0.008). Western blotting analysis verified that PRDM14 associated with cell differentiation in NSCLC. The overall survival rates of patients with high PRDM14 expression and low PRDM14 expression were 41.30 and 65.06 %, respectively (hazard ratio: 3.051, 95 % CI: 1.752, 5.312, P < 0.0001). The progression-free survival rates were 34.78 % for patients in the high expression group and 59.03 % for patients in the low OLC1 expression group (hazard ratio: 2.775, 95 % CI: 1.648, 4.675, P < 0.0001). Thus, our study showed that increased expression of PRDM14 correlated with cell differentiation of NSCLC cells. PRDM14 was a potential biomarker for predicting unfavorable prognosis in NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.